We recently published a list of Jim Cramer is Talking About These 10 Stocks. In this article, we are going to take a look at ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and ...

Argus Research analyst David Toung maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday. The company’s shares ...

Johnson & Johnson (JNJ) stock saw a modest uptick, ending the day at $152.89 which represents a slight increase of $6.07 or 4.13% from the prior close of $146.82. The stock opened at $ and touched a ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

JNJ boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Johnson & Johnson are trading at a forward earnings multiple of 14.5X, as well as a PEG Ratio ...